Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial

被引:31
作者
Bray, G. A. [1 ]
Smith, S. R. [2 ,3 ]
Banerji, M. A. [4 ]
Tripathy, D. [5 ,6 ]
Clement, S. C. [7 ]
Buchanan, T. A. [8 ]
Henry, R. R. [9 ]
Kitabchi, A. E. [10 ]
Mudaliar, S. [9 ]
Musi, N. [5 ,6 ]
Ratner, R. E. [11 ]
Schwenke, D. C. [12 ,13 ]
Stentz, F. B. [10 ]
Reaven, P. D. [13 ]
DeFronzo, R. A. [5 ,6 ]
机构
[1] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA
[2] Florida Hosp, Orlando, FL USA
[3] Sanford Burnam Res Inst, Orlando, FL USA
[4] SUNY Hlth Sci Ctr, Brooklyn, NY USA
[5] Texas Diabet Inst, San Antonio, TX USA
[6] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[7] Georgetown Univ, Div Endocrinol & Metab, Washington, DC USA
[8] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA
[9] Univ Calif San Diego, VA San Diego Healthcare Syst, San Diego, CA 92103 USA
[10] Univ Tennessee, Div Endocrinol Diabet & Metab, Memphis, TN USA
[11] Medstar Res Inst, Hyattsville, MD USA
[12] Arizona State Univ, Coll Nursing & Hlth Innovat, Phoenix, AZ USA
[13] Phoenix Vet Affairs VA Hlth Care Syst, Phoenix, AZ USA
关键词
clinical trial; fat; glycaemic control; TYPE-2; DIABETES-MELLITUS; X-RAY ABSORPTIOMETRY; BETA-CELL FUNCTION; INSULIN SENSITIVITY; FAT DISTRIBUTION; HISPANIC WOMEN; PPAR-GAMMA; LIVER FAT; ROSIGLITAZONE; GLUCOSE;
D O I
10.1111/dom.12099
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: This study examined the effects of pioglitazone on body weight and bone mineral density (BMD) prospectively in patients with impaired glucose tolerance as pioglitazone (TZD) increases body weight and body fat in diabetic patients and increases the risk of bone fractures. Methods: A total of 71 men and 163 women aged 49.3 (10.7) years [mean (s.d.)]; body mass index (BMI), 34.5 (5.9) kg/m(2) were recruited at five sites for measurements of body composition by dual energy X-ray absorptiometry at baseline and at conversion to diabetes or study end, if they had not converted. Results: Mean follow-up was 33.6 months in the pioglitazone group and 32.1 months in the placebo group. Body weight increased 4.63 +/- 0.60 (m +/- s.e.) kg in the pioglitazone group compared to 0.98 +/- 0.62 kg in the PIO group (p < 0.0001). Body fat rose 4.89 +/- 0.42 kg in the pioglitazone group compared to 1.41 +/- 0.44 kg, (p < 0.0001) in placebo-treated subjects. The increase in fat was greater in legs and trunk than in the arms. BMD was higher in all regions in men and significantly so in most. PIO decreased BMD significantly in the pelvis in men and women, decreased BMD in the thoracic spine and ribs of women and the lumbar spine and legs of men. Bone mineral content also decreased significantly in arms, legs, trunk and in the total body. Conclusions: Pioglitazone increased peripheral fat more than truncal fat and decreased BMD in several regions of the body.
引用
收藏
页码:931 / 937
页数:7
相关论文
共 41 条
[1]  
[Anonymous], BR J DIABETES VASC D, DOI DOI 10.1177/14746514050050010601
[2]  
[Anonymous], DIAB PROGR FACTS FIG
[3]   Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes [J].
Aubert, R. E. ;
Herrera, V. ;
Chen, W. ;
Haffner, S. M. ;
Pendergrass, M. .
DIABETES OBESITY & METABOLISM, 2010, 12 (08) :716-721
[4]   Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients [J].
Bajaj, M ;
Suraamornkul, S ;
Hardies, LJ ;
Pratipanawatr, T ;
DeFronzo, RA .
INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 (06) :783-789
[5]   Effects of Pioglitazone on Intramyocellular Fat Metabolism in Patients with Type 2 Diabetes Mellitus [J].
Bajaj, Mandeep ;
Baig, Rais ;
Suraamornkul, Swangjit ;
Hardies, Lou Jean ;
Coletta, Dawn K. ;
Cline, Gary W. ;
Monroy, Adriana ;
Koul, Shailja ;
Sriwijitkamol, Apiradee ;
Musi, Nicolas ;
Shulman, Gerald I. ;
DeFronzo, Ralph A. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (04) :1916-1923
[6]   Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach [J].
Bays, H ;
Mandarino, L ;
DeFronzo, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) :463-478
[7]   Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial [J].
Coletta, D. K. ;
Sriwijitkamol, A. ;
Wajcberg, E. ;
Tantiwong, P. ;
Li, M. ;
Prentki, M. ;
Madiraju, M. ;
Jenkinson, C. P. ;
Cersosimo, E. ;
Musi, N. ;
DeFronzo, R. A. .
DIABETOLOGIA, 2009, 52 (04) :723-732
[8]   Prevalence of diabetes and impaired fasting glucose in adults in the US population - National Health and Nutrition Examination Survey 1999-2002 [J].
Cowie, Catherine C. ;
Engelgau, Michael M. ;
Rust, Keith F. ;
Saydah, Sharon H. ;
Byrd-Holt, Danita D. ;
Williams, Desmond E. ;
Eberhardt, Mark S. ;
Geiss, Linda S. ;
Flegal, Katherine M. ;
Gregg, Edward W. .
DIABETES CARE, 2006, 29 (06) :1263-1268
[9]   Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance [J].
DeFronzo, Ralph A. ;
Tripathy, Devjit ;
Schwenke, Dawn C. ;
Banerji, MaryAnn ;
Bray, George A. ;
Buchanan, Thomas A. ;
Clement, Stephen C. ;
Henry, Robert R. ;
Hodis, Howard N. ;
Kitabchi, Abbas E. ;
Mack, Wendy J. ;
Mudaliar, Sunder ;
Ratner, Robert E. ;
Williams, Ken ;
Stentz, Frankie B. ;
Musi, Nicolas ;
Reaven, Peter D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (12) :1104-1115
[10]   Actos Now for the prevention of diabetes (ACT NOW) study [J].
DeFronzo, Ralph A. ;
Banerji, MaryAnn ;
Bray, George A. ;
Buchanan, Thomas A. ;
Clement, Stephen ;
Henry, Robert R. ;
Kitabchi, Abbas E. ;
Mudaliar, Sunder ;
Musi, Nicolas ;
Ratner, Robert ;
Reaven, Peter D. ;
Schwenke, Dawn ;
Stentz, Frankie B. ;
Tripathy, Devjit .
BMC ENDOCRINE DISORDERS, 2009, 9